Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

Evanthia Galanis, Pamela J. Atherton, Matthew J. Maurer, Keith L Knutson, Sean Christopher Dowdy, William Arthur Cliby, Paul Haluska, Harry J. Long, Ann L Oberg, Ileana Aderca, Matthew S Block, Jamie N Bakkum-Gamez, Mark J Federspiel, Stephen J Russell, Kimberly R. Kalli, Gary Keeney, Kah-Whye Peng, Lynn C. Hartmann

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Edmonstonvaccinestrains ofmeasles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian cancer. MV engineered to express the sodium iodide symporter gene (MVNIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Here, we report results from a clinical evaluation of MV-NIS inpatients with taxol- and platinum-resistant ovarian cancer. MV-NIS was given intraperitoneally every 4 weeks for up to 6 cycles. Treatment was well tolerated and associated with promising median overall survival in these patients with heavily pretreated ovarian cancer; no dose-limiting toxicitywas observed in 16 patients treated at high-dose levels (108-109 TCID50), and their median overall survival of 26.5 months compared favorably with other contemporary series. MV receptor CD46 and nectin-4 expression was confirmed by immunohistochemistry in patient tumors. Sodium iodide symporter expression in patient tumors after treatment was confirmed in three patients by 123I uptake on SPECT/CTs and was associated with long progression-free survival. Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect. Our findings support further clinical evaluation of MV-NIS as an effective immunovirotherapy.

Original languageEnglish (US)
Pages (from-to)22-30
Number of pages9
JournalCancer Research
Volume75
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Oncolytic Viruses
Measles virus
Ovarian Neoplasms
Pharmaceutical Preparations
Neoplasms
Immunologic Monitoring
Survival
Viral Genes
Neoplasm Antigens
Paclitaxel
Platinum
Heterografts
Cellular Immunity
Disease-Free Survival
sodium-iodide symporter
Inpatients
Therapeutics
Immunohistochemistry
Viruses
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. / Galanis, Evanthia; Atherton, Pamela J.; Maurer, Matthew J.; Knutson, Keith L; Dowdy, Sean Christopher; Cliby, William Arthur; Haluska, Paul; Long, Harry J.; Oberg, Ann L; Aderca, Ileana; Block, Matthew S; Bakkum-Gamez, Jamie N; Federspiel, Mark J; Russell, Stephen J; Kalli, Kimberly R.; Keeney, Gary; Peng, Kah-Whye; Hartmann, Lynn C.

In: Cancer Research, Vol. 75, No. 1, 01.01.2015, p. 22-30.

Research output: Contribution to journalArticle

@article{36ee3acbb74d48ac9a01e9c5a463961b,
title = "Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer",
abstract = "Edmonstonvaccinestrains ofmeasles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian cancer. MV engineered to express the sodium iodide symporter gene (MVNIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Here, we report results from a clinical evaluation of MV-NIS inpatients with taxol- and platinum-resistant ovarian cancer. MV-NIS was given intraperitoneally every 4 weeks for up to 6 cycles. Treatment was well tolerated and associated with promising median overall survival in these patients with heavily pretreated ovarian cancer; no dose-limiting toxicitywas observed in 16 patients treated at high-dose levels (108-109 TCID50), and their median overall survival of 26.5 months compared favorably with other contemporary series. MV receptor CD46 and nectin-4 expression was confirmed by immunohistochemistry in patient tumors. Sodium iodide symporter expression in patient tumors after treatment was confirmed in three patients by 123I uptake on SPECT/CTs and was associated with long progression-free survival. Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect. Our findings support further clinical evaluation of MV-NIS as an effective immunovirotherapy.",
author = "Evanthia Galanis and Atherton, {Pamela J.} and Maurer, {Matthew J.} and Knutson, {Keith L} and Dowdy, {Sean Christopher} and Cliby, {William Arthur} and Paul Haluska and Long, {Harry J.} and Oberg, {Ann L} and Ileana Aderca and Block, {Matthew S} and Bakkum-Gamez, {Jamie N} and Federspiel, {Mark J} and Russell, {Stephen J} and Kalli, {Kimberly R.} and Gary Keeney and Kah-Whye Peng and Hartmann, {Lynn C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-14-2533",
language = "English (US)",
volume = "75",
pages = "22--30",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

AU - Galanis, Evanthia

AU - Atherton, Pamela J.

AU - Maurer, Matthew J.

AU - Knutson, Keith L

AU - Dowdy, Sean Christopher

AU - Cliby, William Arthur

AU - Haluska, Paul

AU - Long, Harry J.

AU - Oberg, Ann L

AU - Aderca, Ileana

AU - Block, Matthew S

AU - Bakkum-Gamez, Jamie N

AU - Federspiel, Mark J

AU - Russell, Stephen J

AU - Kalli, Kimberly R.

AU - Keeney, Gary

AU - Peng, Kah-Whye

AU - Hartmann, Lynn C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Edmonstonvaccinestrains ofmeasles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian cancer. MV engineered to express the sodium iodide symporter gene (MVNIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Here, we report results from a clinical evaluation of MV-NIS inpatients with taxol- and platinum-resistant ovarian cancer. MV-NIS was given intraperitoneally every 4 weeks for up to 6 cycles. Treatment was well tolerated and associated with promising median overall survival in these patients with heavily pretreated ovarian cancer; no dose-limiting toxicitywas observed in 16 patients treated at high-dose levels (108-109 TCID50), and their median overall survival of 26.5 months compared favorably with other contemporary series. MV receptor CD46 and nectin-4 expression was confirmed by immunohistochemistry in patient tumors. Sodium iodide symporter expression in patient tumors after treatment was confirmed in three patients by 123I uptake on SPECT/CTs and was associated with long progression-free survival. Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect. Our findings support further clinical evaluation of MV-NIS as an effective immunovirotherapy.

AB - Edmonstonvaccinestrains ofmeasles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian cancer. MV engineered to express the sodium iodide symporter gene (MVNIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Here, we report results from a clinical evaluation of MV-NIS inpatients with taxol- and platinum-resistant ovarian cancer. MV-NIS was given intraperitoneally every 4 weeks for up to 6 cycles. Treatment was well tolerated and associated with promising median overall survival in these patients with heavily pretreated ovarian cancer; no dose-limiting toxicitywas observed in 16 patients treated at high-dose levels (108-109 TCID50), and their median overall survival of 26.5 months compared favorably with other contemporary series. MV receptor CD46 and nectin-4 expression was confirmed by immunohistochemistry in patient tumors. Sodium iodide symporter expression in patient tumors after treatment was confirmed in three patients by 123I uptake on SPECT/CTs and was associated with long progression-free survival. Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect. Our findings support further clinical evaluation of MV-NIS as an effective immunovirotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84920644561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920644561&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2533

DO - 10.1158/0008-5472.CAN-14-2533

M3 - Article

VL - 75

SP - 22

EP - 30

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -